Neurotech International (ASX:NTI) Signs New Development Agreement for Cannabinoid Therapies

Highlights:

Key Points:

• Neurotech enters partnership agreement with RH Farma Dooel Skopje (RH Pharma), a subsidiary of European Cannabis Company (ECC), a European leader in the development and scale-up of cannabis-based products for pharmaceutical applications
• The development aims to generate a strain-agnostic, pharmaceutical-grade broad spectrum cannabinoid drug product suitable for paediatric patients with neurodevelopmental disorders based on RH Pharma’s proprietary CO2 extraction technology
• Aligns with Neurotech’s position and formulation consisting of certain cannabinoidsat specific concentrations that has demonstrated significant improvement in patients with
  progressive neuroinflammatory disorders including autism, Rett Syndrome and PANDAS/PANS
• An Initial upfront payment of €25,000 with additional services as requested by Neurotech with an initial term of 12 months

Overview:

Neurotech International Limited, a clinical-stage biopharmaceutical development company focused predominately on pediatric neurological disorders, today announced the signing of a binding Development Agreement with RH Pharma, a European leader in the development and scale-up of cannabis-based products for pharmaceutical applications.

Under the agreement, Neurotech will harness ECC’s advanced capabilities in product development, manufacturing, and scale up to meet the increasing global demand for high-quality cannabis-derived pharmaceuticals. Under the development plans, RH Pharma will undertake a controlled recombination process of highly purified cannabinoids from standard cannabis strains under Good Manufacturing Practice (GMP), and relevant other pharmaceutical standards, into a broad-spectrum cannabinoid drug product reflecting Neurotech’s compositional standards, and that meets global regulatory standards. The partnership allows both companies to leverage their expertise to deliver consistent, high performing products to international markets.

The Development Agreement will enable Neurotech to expand into new markets while ensuring production at the highest pharmaceutical standards. Neurotech’s commitment to innovation has culminated in the development of proprietary technologies and processes that enhance product efficacy and safety.

Company Notes:

Dr Anthony Filippis, CEO and Managing Director of Neurotech International said “As we accelerate our plans for registration of NTI64 in Australia via a provisional registration strategy initially, it will be important for Neurotech to scale production to meet future product demand upon regulatory approval(s). Our commitment to regulatory compliance and quality is further strengthened by collaborations with leading medical institutions and key clinicians, reinforcing our position within the industry. We are delighted to partner with ECC, a company renowned for its expertise in cannabis product development. This agreement not only accelerates our global growth strategy but also ensures we can deliver premium-quality products with unparalleled consistency and scalability, independent of strain specific limitations.

“ECC is thrilled to collaborate with Neurotech on this transformative partnership,” said Rebeka Levy, General Manager of European Cannabis Company. “Our shared vision for innovation and international expansion positions us to deliver exceptional products to meet growing global demand.”

The Development Agreement aligns with the Company’s focus on innovation and making a meaningful difference in the lives of those affected by neurological disorders

Full ASX Announcement: Neurotech International ASX Announcement